CN470 has notable anti-tumor activity against MLL1-rearranged ALL by binding to the bromodomains (BRDs) of BRD4, CREBBP, and EP300 in vitro and in vivo [70]. The gene discussed is EP300; the disease is acute lymphoblastic leukemia.